Category Archives: Analysis

Analysis: Why Dental Care Costs So Much In The U.S.

Americans have a tendency to avoid the dentist. More than 40% of Americans said they don’t see a dentist as often as they would like, according to a 2018 survey by the American Dental Association.

Their number one reason for skipping visits is cost, even among those with dental insurance. Dental insurance policies can be confusing and difficult to use, making some Americans wonder whether dental insurance is worth investing in at all. Watch the video to find out to learn what it actually costs to go to the dentist, whether dental insurance is worth investing in and what patients and policymakers can do about it.

Chapters 0:00 – Introduction 1:42 – How dental insurance works 4:15 – Dental care costs 6:17 – Is dental insurance worth it? 9:49 – Solutions Americans have a tendency to avoid the dentist. More than 40% of Americans said they don’t see a dentist as often as they would like, according to a 2018 survey by the American Dental Association. People have lots of reasons for not going, including fear, inconvenience and trouble finding a dentist who take their insurance. But the top reason Americans cite for avoiding the dentist is cost, with nearly 60% of Americans saying cost was the main reason they haven’t visited the dentist in the past 12 months. Cost remained the number one reason regardless of age, income level or type of insurance. Dental insurance can be confusing since it’s considered a separate service from medical insurance, which means it has different policies and procedures that many patients are not familiar with. From a lack of transparency about benefits to rules like annual maximums — which means plans stop paying for treatment after hitting a certain amount for the year — some patients question whether dental insurance is worth investing in at all. “There’s this misnomer that you need dental insurance to go to the dentist, you really don’t,” said Dr. Mark Vitale, a general dentist and owner of Edison Dental Arts in Edison, New Jersey. “Dental insurance is not the panacea that most people think it is.” But the industry landscape is shifting as more traditional health insurance companies are supplementing their medical plans with dental benefits. “Dental insurance is extremely profitable to the insurance companies, which is why many of the insured many of the major carriers offer dental insurance,” Vitale said.

Analysis: $131 Trillion To Reduce Global Warming

Money is a sticking point in climate-change negotiations around the world. As economists warn that limiting global warming to 1.5 degrees Celsius will cost many more trillions than anticipated, WSJ looks at how the funds could be spent, and who would pay. Illustration: Preston Jessee/WSJ

Analysis: China’s New Regulations On Tech

Big Tech, real estate, and even video games are being targeted by new regulations in China. This regulatory upheaval could be yet another sign that Xi Jinping and the Chinese Communist Party is trying to reign in the business sector.

Analysis: Food’s Future In A More Sustainable World

Over one-third of greenhouse-gas emissions come from food production. For a greener future, this urgently needs to change. What’s the future of food in a more sustainable world? Our experts answer your questions.

Video timeline: 00:00 – Food’s environmental impact 00:44 – Why it’s important to make food sustainable 01:34 – Will everyone have to give up meat? 02:13 – Can lab-grown meat be scaled up? 03:32 – Could nutrients and vitamins be added to new foods? 04:52 – Will insects become a new staple food? 05:35 – Why small-scale farming isn’t the main solution 06:51 – Is vertical farming more sustainable? 07:36 – Will consumers accept new foods?

Covid-19: How BioNTech Used Its Cancer Research To Create A Vaccine (CNBC)

Over a month and a half before the World Health Organization officially declared a pandemic, BioNTech CEO Uğur Şahin met with his wife, BioNTech’s co-founder and chief medical officer Özlem Türeci, and together they agreed to redirect most of the company’s resources to developing a vaccine. Up until that point, BioNTech was little-known internationally and primarily focused on developing novel cancer treatments. The founders were confident in the potential of their mRNA technology, which they knew could trigger a powerful immune response. That confidence wasn’t necessarily shared by the broader medical community. No mRNA vaccine or treatment had ever been approved before. But the couple’s timely breakthrough was actually decades in the making. CNBC spoke with Şahin and Türeci about how they, along with Pfizer, created a Covid-19 vaccine using mRNA.

Analysis: The Cargo Ship Congestion In Los Angeles

California’s Port of Los Angeles is struggling to keep up with the crush of cargo containers arriving at its terminals, creating one of the biggest choke points in the global supply-chain crisis. This exclusive aerial video illustrates the scope of the problem and the complexities of this process. Photo: Thomas C. Miller

Employment: Why Millions Of Workers Are Quitting

Americans are leaving their jobs in droves. In August 4.3 million Americans quit their jobs. While some people have left the workforce entirely, job security and better pay are top concerns for others. Dubbed “The Great Resignation”, the exodus of workers has created hiring challenges for companies and left millions of jobs unfilled. More than half of U.S. workers surveyed said they plan to look for a new job in the coming year, according to Bankrate’s August jobseeker survey. Some 56% of respondents said adjustable working hours and remote work were a priority. Working women have faced an additional burden, juggling childcare duties, virtual schooling and their careers. So, what does the realignment of the workforce mean for employees and businesses? And what steps should you take before quitting your job?

Covid-19: Molnupiravir – Merck’s Antiviral Drug

Molnupiravir (MK-4482, EIDD-2801) is an investigational oral antiviral medicine that significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.

Analysis: Green Era Energy Shock, From Pandemic To Endemic, Poland’s ‘Polexit’

A selection of three essential articles read aloud from the latest issue of The Economist. This week, the first big energy shock of the green era, how covid-19 will move from pandemic to endemic (11:29) and our Charlemagne columnist assesses the odds of “Polexit” versus a “dirty remain” (17:21).